

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8955 — Takeda/Shire

SECTION 1.2

Description of the concentration

- (1) On 8 May 2018, the boards of Takeda Pharmaceutical Company Limited ("**Takeda**") and Shire plc ("**Shire**") announced that they had reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire. It is proposed that the acquisition will be effected by means of a scheme of arrangement of Shire under Jersey Law, by which Takeda will acquire sole control of Shire within the meaning of Article 3(1) of the Merger Regulation.
- (2) Takeda, incorporated in Japan, is a global, R&D-driven pharmaceutical company, which focuses its research efforts on four key therapeutic areas: Oncology, Gastroenterology, Neuroscience and Vaccines. For more information, please see www.takeda.com.
- (3) Shire, incorporated in Jersey, is a global biotechnology company focused on serving patients with rare diseases and other highly specialised conditions across core therapeutic areas, including: Immunology, Hematology, Neuroscience, Internal medicine, Genetic diseases and Ophthalmics. For more information, please see www.shire.com.